Perifosine in Treating Patients With Metastatic, Androgen-Independent Prostate Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed adenocarcinoma of the prostate, meeting all of the following criteria:
• * Metastatic
• * Androgen-independent
• * Progressive disease while continuing to receive hormonal ablation (e.g., luteinizing hormone-releasing hormone \[LHRH\] agonist)
• Progression documented by at least 1 of the following parameters:
• * Two consecutively rising prostate-specific antigen levels, at least 1 week apart, with at least 1 measurement that is 50% above the nadir reached after the last treatment regimen (as long as the last measurement is at least 5 ng/mL)
• * At least 1 new metastatic lesion on technetium Tc 99m bone scintigraphy
• * Progression of soft-tissue metastases as measured by appropriate modalities (i.e., imaging or palpation) and demonstrated by at least 1 of the following:
• * Development of new area of malignant disease (measurable or nonmeasurable)
• * At least a 20% increase in the sum of the longest diameters (LD) of target lesions from the smallest sum of LD recorded since the treatment started or the appearance of 1 or more new lesions
• Patients who have not undergone surgical castration must have a testosterone level less than 50 ng/mL and continue on their LHRH agonist during study treatment
• No known brain metastases
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• ECOG 0-2 OR
• Karnofsky 60-100%
• Life expectancy
• More than 3 months
• Hematopoietic
• WBC at least 3,000/mm\^3
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Hepatic
• Bilirubin less than 1.0 mg/dL or upper limit of normal (ULN)
• AST/ALT no greater than 2.5 times ULN
• Renal
• Creatinine no greater than 1.5 mg/dL OR
• Creatinine clearance at least 60 mL/min
• Cardiovascular
• No myocardial infarction within the past 6 months
• No unstable or newly diagnosed angina pectoris
• No New York Heart Association class II-IV congestive heart failure
• Ophthalmic
• No pre-existing retinal disease
• No pathologic baseline electrooculogram
• Other
• Fertile patients must use effective barrier contraception
• Able to ingest oral medication
• No prior allergic reactions attributed to compounds of similar chemical or biological composition to perifosine (e.g., miltefosine or edelfosine)
• No ongoing or active infection
• No other concurrent uncontrolled illness
• No psychiatric illness or social situation that would preclude study compliance
• No other active malignancies within the past 2 years except nonmelanoma skin cancer or carcinoma in situ of the bladder
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• Not specified
• Chemotherapy
• No more than 1 prior chemotherapy regimen
• More than 4 weeks since prior chemotherapy (at least 6 weeks for nitrosoureas or mitomycin)
• Endocrine therapy
• See Disease Characteristics
• More than 4 weeks since prior flutamide
• More than 6 weeks since prior bicalutamide or nilutamide
• Radiotherapy
• At least 6 weeks since prior bone-seeking radioisotopes
• Recovered from prior radiotherapy
• Surgery
• See Disease Characteristics
• Recovered from prior surgery
• Other
• Recovered from any acute toxicity related to prior therapy
• More than 3 months since prior UCN-01
• More than 3 months since prior suramin
• No concurrent commercial or other investigational agents or therapies intended to treat the malignancy
• No concurrent combination antiretroviral therapy for HIV-positive patients